Optimizing and Individualizing IVIG Therapy in CIDP

In "Optimizing and Individualizing IVIG Therapy in CIDP," our panel explores the nuanced clinical decision-making required to optimize immunoglobulin therapy for patients with CIDP beyond standard protocol dosing. The discussion opens with the challenge of determining the right dose and frequency for each patient, with panelists agreeing that while the ICE trial dosing protocol serves as a useful starting point, individual disease severity, insurance constraints, and treatment response all influence real-world dosing decisions. One expert notes a preference for erring toward more aggressive dosing in patients with active or progressive disease, given that undertreating CIDP can result in irreversible disability. Periodic monitoring with nerve conduction studies and peripheral nerve ultrasound is also highlighted as a strategy for detecting subclinical progression even in clinically stable patients.

The panel then addresses the challenge of dose tapering, acknowledging that approximately one-third of patients can achieve remission, making periodic reassessment of immunoglobulin requirements an important clinical practice. Panelists share differing but complementary approaches to tapering — some prefer extending the dosing interval while others favor reducing the total dose — with both strategies considered acceptable in the absence of definitive comparative evidence. The immunoglobulin half-life of 21 to 28 days is cited as a rationale for maintaining a three-to-four week interval while reducing dose. Panelists uniformly emphasize caution when tapering, recommending a minimum observation period of three months following any dose adjustment before drawing conclusions about the change.

The GAMEDIS study is then reviewed as supportive long-term real-world evidence, demonstrating that immunoglobulin therapy maintained stability in disability, depression, and fatigue scales over approximately two years, with minimal patient dropout. While panelists express a desire to see improvement rather than mere stabilization in quality-of-life measures, the findings are characterized as reassuring for long-term tolerability and sustained disease control. The episode closes with a discussion of practical barriers to dose escalation, including infusion duration burden at higher doses, volume limitations with subcutaneous administration, frequency constraints for patients receiving intravenous infusions every two weeks or more often, and systemic side effects associated with high-volume immunoglobulin therapy.